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Abstract
 
In lupus-prone NZM2328 mice, a locus 
 
Cgnz1
 
 on chromosome 1 was linked to chronic
glomerulonephritis, severe proteinuria, and early mortality in females. A locus 
 
Adnz1
 
 on chro-
mosome 4 was linked to antinuclear antibody (ANA) and anti–double stranded DNA (dsDNA)
antibody (Ab) production. In this investigation, two congenic strains, NZM2328.C57L/Jc1
(NZM.C57Lc1) and NZM2328.C57L/Jc4 (NZM.C57Lc4), were generated by replacing the
respective genetic intervals containing either 
 
Cgnz1
 
 or 
 
Adnz1
 
 with those from C57L/J, a
nonlupus-prone strain. The NZM.C57Lc1 females had markedly reduced incidence of chronic
glomerulonephritis and severe proteinuria. NZM.C57Lc4 females had chronic glomerulone-
phritis and severe proteinuria without circulating ANA, anti-dsDNA, and antinucleosome Ab.
These data confirm the linkage analysis. Unexpectedly, NZM.C57Lc1 females had little anti-
dsDNA and related Ab, suggesting the presence of a second locus 
 
Adnz2
 
 on chromosome 1.
The diseased NZM.C57Lc4 kidneys had immune complexes by immunofluorescence and
electron microscopy. The eluates from these kidneys did not contain ANA, anti-dsDNA, and
antinucleosome Ab, indicative of the presence of non–anti-dsDNA nephritogenic Ab. Thus,
breaking tolerance to dsDNA and chromatin is not required for the pathogenesis of lupus
nephritis. These results reaffirm that anti-dsDNA and related Ab production and chronic
glomerulonephritis are under independent genetic control. These findings have significant
implications in the pathogenesis of systemic lupus erythematosus.
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Introduction
 
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease with multiple autoantibodies as a hallmark. In par-
ticular, the presence of antinuclear Ab (ANA) is a dominant
feature of this disorder and is considered one of the diag-
nostic criteria (1, 2). Chronic glomerulonephritis with severe
proteinuria and renal failure is a major complication of
SLE. Anti–double stranded DNA (dsDNA) and antinu-
cleosome Ab have been said to play major roles in its
pathogenesis (3–10). From a series of experiments using
NZM2410 as a mouse model for SLE, others have con-
cluded that loss of tolerance to nuclear Ags such as dsDNA
and nucleosome manifested by the production of ANA is
an initial and central step in the pathogenesis of lupus glo-
merulonephritis (11–16). These and other studies have led
to the current dogma that ANA, anti-dsDNA, and antinu-
cleosome autoantibodies are of paramount importance in
the pathogenesis of SLE (17, 18).
Recently, our laboratory has characterized a new lupus-
prone strain NZM2328, which shows female bias in
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chronic glomerulonephritis with both males and females
producing ANA, anti-dsDNA Ab, and acute glomerulone-
phritis. Five lupus susceptibility genetic intervals were
identified in NZM2328 in the analysis of the backcross
(C57L/JXNZM2328)F1XNZM2328 (19). In this study,
acute glomerulonephritis was characterized by hypercellu-
lar glomeruli with little or no glomerulosclerosis, and with-
out interstitial fibrosis or tubular atrophy/dilatation. In
contrast, extensive glomerulosclerosis, interstitial fibrosis,
and tubular atrophy/dilatation were diagnostic of chronic
glomerulonephritis. Our previous study has documented
association of severe proteinuria with chronic but not with
acute glomerulonephritis (19). Based on these diagnostic
criteria, a single locus 
 
Cgnz1
 
 was significantly linked to
chronic glomerulonephritis, severe proteinuria, and early
mortality in female mice. Three genetic intervals, 
 
Agnz1
 
distal to 
 
Cgnz1
 
 on chromosome 1, and the 
 
H-2
 
 complex
and 
 
Agnz2
 
 distal to H-2 on chromosome 17, were sugges-
tively linked to acute glomerulonephritis. A single locus
 
Adnz1
 
 on chromosome 4 was suggestively linked to ele-
vated levels of ANA and anti-dsDNA Ab.
In this investigation, two congenic strains of NZM2328
were generated by the microsatellite marker-assisted method
(20, 21). NZM2328.C57L/Jc1 (NZM.C57Lc1) was gener-
ated by replacing the segment of chromosome 1, which
contains 
 
Cgnz1
 
 and 
 
Agnz1
 
 in NZM2328 with that of
C57L/J. NZM2328.C57L/Jc4 (NZM.C57Lc4) was simi-
larly generated. Serological, histological, and kidney elution
studies provided convincing evidence that chronic lupus ne-
phritis could be initiated without detectable ANA, antinu-
cleosome, and anti-dsDNA autoantibody production. Thus,
an alternative hypothesis to the current dogma that breaking
tolerance to nuclear Ags is the initial and the most important
step in lupus pathogenesis should be reconsidered.
 
Materials and Methods
 
Mice.
 
NZM 2328Aeg breeding pairs were obtained from
The Jackson Laboratory. The NZM2328 line has been main-
tained in our colony for more than 10 generations by brother-sis-
ter mating with no change in serological characteristics or the in-
cidence of renal disease. C57L/J females were obtained from The
Jackson Laboratory to generate (C57L/JXNZM2328) F1. All
mice were housed under pathogen-free conditions at the Uni-
versity of Virginia Animal Care Facility. NZM.C57Lc1 and
NZM.C57Lc4 were generated using a microsatellite marker-
assisted speed congenic generation protocol (20, 21). In brief, fe-
male (C57L/JXNZM2328) F1 mice were backcrossed to male
NZM2328 mice. Four additional backcrosses were performed.
This was followed by inbreeding through brother-sister mating.
The number of backcrosses was found to be sufficient to generate
heterozygotes for either the chromosome 1 or chromosome 4 re-
gions on NZM2328 background. Genotypes were determined by
PCR amplification of polymorphic microsatellite markers from
genomic DNA using map pairs oligonucleotides (Research Ge-
netics). The markers used have been described (19). After each
backcross and intercross, breeders were chosen for their carrying
the largest portion of the interested intervals of either chromo-
some 1 or chromosome 4 from C57L/J and the least amounts of
donor DNA throughout the rest of the genome.
Figure 1. NZM.C57Lc1 and NZM.C57Lc4 congenic lines were derived
by replacing the genetic intervals in NZM2328 with those from C57L/J
(hatched bars). The genetic intervals with SLE susceptibility genes in
NZM2328 delineated by informative microsatellite markers are shown
(open bars). Chromosome intervals are not drawn to scale.
Figure 2. Development of severe proteinuria in females of NZM2328
and NZM.C57Lc4 but not in those of NZM.C57Lc1. (A) Incidence of
severe proteinuria in each strain of mice. (B) Kinetics of proteinuria
development. 
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Clinical and Histological Assessment.
 
Screening for severe pro-
teinuria (
 
 
 
300 mg/dL on two occasions) and histological and
immunofluorescence studies of kidneys were performed as previ-
ously described (19). An electron microscopic (EM) study of the
kidneys was performed by the University of Virginia Central EM
Facility. Kidney slices were fixed in 2% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4, at 4
 
 
 
C overnight. The tissue was
washed in buffer followed by incubation at room temperature
with 2% osmium tetroxide in buffer for 1 h. The tissue was then
dehydrated with acetone and embedded in EPON. One-half mi-
cron sections were cut and stained with toludine blue and exam-
ined under light microscopy. Ultrathin sections of 
 
 
 
70–80 nm in
thickness from the area of interest were counterstained with lead
citrate and uranyl acetate. They were examined using a JEOL
100-CX transmission electron microscope.
 
Serological Assays.
 
ANAs were detected by indirect immu-
nofluorescence microscopy using either HeLa or NIH/3T3 cells
as substrates and anti-dsDNA Abs were detected by ELISA as
previously described (19). Serial dilutions of a monoclonal Ab
(R4A) to dsDNA (provided by B. Diamond, Albert Einstein
College of Medicine, Bronx, NY) were used as standard and data
are presented as units/microgram IgG. Antinucleosome Ab was
assayed by ELISA with histone/dsDNA as the substrate accord-
ing to the procedure described by Mohan et al. (10). Sera were
assayed at 1/50 dilution for ANA and 1/100 dilution for ELISA.
Rheumatoid factor activity was assayed with either human or
rabbit IgG as the substrate as described by Fang et al. (22). Anti-
histone H1 ELISA was performed with purified H1 as the sub-
strate. Western blot analysis was performed as previously de-
scribed (23). WEHI 7.1 lymphoma cells, kidney, and liver
extracts from 8-wk-old NZM2328 were used as substrates in
Western blot analysis.
 
Acid Elution of Igs from Kidney.
 
Igs were eluted from the kid-
ney as previously described by Woodroffe and Wilson (24). The
homogenate was centrifuged at 1,200 
 
g
 
 for 10 min at 4
 
 
 
C and
washed in chilled PBS, followed by vortexing and centrifugation
to remove serum proteins. The washings were repeated until the
OD
 
280 
 
of the supernatant was 
 
 
 
0.05. The pellet was then sus-
pended in 0.1 M glycine with 1% BSA, pH 2.8 (10 ml/g kidney),
and mixed gently at 4
 
 
 
C for 20 min. The suspension was centri-
fuged and supernatant was immediately neutralized with 1 M Tris
base. Anti-dsDNA Ab and IgG concentrations in the sera and the
renal eluate were determined by ELISA and expressed as dsDNA
Ab units/microgram IgG.
 
Results
 
Generation of NZM.C57Lc1 and NZM.C57Lc4 Congenic
Lines.
 
A microsatellite marker-assisted protocol was
used to facilitate the generation of both NZM.C57Lc1 and
NZM.C57Lc4. A panel of 91 informative markers was used
for the selection of the breeding pairs. As shown in Fig. 1, the
C57L/J alleles were maintained throughout the genomic in-
terval flanked by D1Mit15 (87.9 cM) and D1Mit155 (112.0
cM) for the derivation of NZM.C57Lc1 and D4Mit91 (15.6
Figure 3. Histological, immunofluorescence, and
EM studies of representative kidneys from
NZM.C57Lc1 and NZM.C57Lc4 female mice. (A) Nor-
mal glomeruli (hematoxylin and eosin staining,  200)
are seen in NZM.C57Lc1. (B) In contrast, in the
NZM.C57Lc4 congenic, enlarged glomeruli with
mesangial proliferation, hypercellularity, obliterated
capillary loops, and glomerulosclerosis are evident.
(C) Immunofluorescence studies show some mesangial
IgG deposits in NZM.C57Lc1, similar to the pattern
seen in aged C57L/J. (D) A coarsely granular staining
pattern of IgG deposits in both the mesangia and periph-
eral capillary walls of the glomeruli of NZM.C57Lc4.
(E) Staining of the Bowman capsule and mesangia with
anti-C3 Ab are seen in NZM.C57Lc1. (F) Coarsely
granular staining by anti-C3 Ab throughout the
glomeruli is seen in NZM.C57Lc4. (G) EM study
shows normal glomeruli without electron-dense deposits
in the subepithelial or subendothelial spaces ( 10,000)
in the kidney of NZM.C57Lc1. (H) In comparison,
electron-dense deposits in both subendothelial space
(arrow) and the mesangia (arrowheads) in the glomeruli
of NZM.C57Lc4 are readily detected. 
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cM) and D4Mit72 (59.9 cM) for NZM.C57Lc4. Each of
these genetic intervals contains the 95% confidence interval
for the loci linked to acute and chronic glomerulonephritis
(
 
Agnz1
 
 and 
 
Cgnz1
 
) on chromosome 1 and to ANA and anti-
dsDNA Ab production (
 
Adnz1
 
) on chromosome 4.
 
Severe Proteinuria and Chronic Glomerulonephritis in
NZM.C57Lc4 but Not in NZM.C57Lc1 Female Mice.
 
Cohorts of NZM.C57Lc1 and NZM.C57Lc4 females were
observed for the development of severe proteinuria and
acute and chronic glomerulonephritis. As shown in Fig. 2
A, 70% (24/34) of NZM.C57Lc4 female mice developed
severe proteinuria and only 3 of the 41 NZM.C57Lc1 fe-
males (7.3%) had severe proteinuria by 12 mo of age. The
incidence of severe proteinuria for NZM.C57Lc4 was simi-
lar to that of parental stain NZM2328. The incidence of se-
vere proteinuria in NZM.C57Lc1 female mice was mark-
edly reduced. The kinetics of proteinuria development
was similar between NZM2328 and its congenic
NZM.C57Lc4. There was a delay of 4 mo in the develop-
ment of severe proteinuria in the three NZM.C57Lc1 mice.
The kidneys from 14 females in each congenic line and
from 44 females of the parental line NZM2328 were evalu-
ated for histological evidence of glomerulonephritis. Acute
glomerulonephritis was defined by the presence of hyper-
cellularity, mesangial proliferation, mononuclear cellular
infiltration, and thickening of the capillary loops. Chronic
glomerulonephritis was scored by the presence of glomeru-
losclerosis tubular atrophy and interstitial fibrosis (16). The
incidences of acute and chronic glomerulonephritis in
NZM2328 at 12 mo of age were 81.8 (36/44) and 52.2%
(23/44), respectively. These incidences were not signifi-
cantly different from those for NZM.C57Lc4 female co-
hort, which had 78.5 (11/14) and 50.0% (7/14) incidences
for acute and chronic glomerulonephritis, respectively. The
three NZM.C57Lc1 females, who developed severe pro-
teinuria, had both acute and chronic glomerulonephritis.
Three of the other NZM.C57Lc1 female mice had acute
glomerulonephritis without chronic glomerulonephritis.
Thus, there was marked reduction in renal disease in the
congenic line NZM.C57Lc1. At the age of 12 mo, no sig-
nificant glomerulonephritis was detected in C57L/J (19).
Histological, immunofluorescence, and EM studies of
representative kidneys of the NZM2328 congenic lines are
shown in Fig. 3. The glomeruli of NZM.C57Lc1 are nor-
mal in size without cellular infiltration and similar to those
seen in kidneys of C57L/J (Fig. 3 A). In contrast, the glom-
eruli of the NZM.C57Lc4 congenic female were enlarged
with hypercellularity, mesangial proliferation, thickened
capillary loops, and segmental glomerulosclerosis (Fig. 3 B).
Although not shown, there were tubular atrophy and inter-
stitial fibrosis in the diseased NZM.C57Lc4 kidneys. Immu-
nofluorescence studies on NZM.C57Lc4 kidneys showed
intense staining for IgG and C3 (Fig. 3, D and F). The
thickened capillary loops were more evident with anti-IgG
staining. Immunofluorescence staining of NZM.C57Lc1
kidneys showed limited staining for IgG in the mesangia
and some C3 deposit in some mesangia and the Bowman
capsule (Figs. 3, C and E). These limited staining patterns
were often seen in aged C57L/J mice and are considered of
no pathological consequences. The IgG and C3 staining
patterns of NZM.C57Lc4 kidneys were suggestive of im-
mune complex–mediated glomerulonephritis. This was con-
firmed by the EM study, showing electron-dense deposits in
the subendothelial and subepithelial areas (Fig. 3 H). In
contrast, a representative EM of NZM.C57c1 kidneys did
not show such electron-dense deposits (Fig. 3 G).
 
Lack of Circulating ANA, Anti-dsDNA, and Antinucleosome
Ab in Both NZM2328 Congenic Lines.
 
Sera from the ter-
minal bleeds of female NZM2328 and its two congenic
Figure 4. Marked reduction of circulating anti-dsDNA, antinuclear,
and antinucleosome Ab in NZM.C57Lc1 and NZM.C57Lc4 congenic
lines in comparison with NZM2328. Staining of HeLa cell nuclei by
DAPI are seen in A, C, and E. The right side of the figure shows the
presence of ANA in the serum of NZM2328 (B) but not in the sera of
NZM.C57Lc1 (D) and NZM.C57Lc4 (F). Although not shown, the
majority of the sera from C57L/J were not positive for ANA. On the
bottom, frequencies of the presence of anti-dsDNA, antinuclear, and
antihistone/DNA Ab in these strains are summarized. 
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lines were analyzed for ANA, anti-dsDNA, and antinu-
cleosome Ab. As shown in the top of Fig. 4, ANAs were
readily detected in the sera of NZM2328 and not in those
of NZM.C57Lc1 and NZM.C57Lc4. The quantitative
data of this study are summarized in the bottom of Fig. 4.
At 1/50 dilution, 19.2% (5/26) of NZM.C57Lc1 sera and
4.5% (1/22) of NZM.C57Lc4 sera were positive for ANAs.
12% of the C57L/J sera at 12 mo of age were positive for
ANAs. For comparison, 53.3% (24/45) of NZM2328 sera
were positive for ANAs. Thus, there were marked reduc-
tions of ANAs in both NZM congenics. Similar marked
reductions in circulating anti-dsDNA and antinucleosome
Figure 5. Lack of RF in sera of NZM2328 and its
congenics. Human IgG was used as the substrate in A
and C to detect anti-IgG activities. Mouse sera were
used at a dilution of 1:50 for A and 1:250 for C. Rabbit
IgG was used as the substrate in B and D with mouse
sera diluted at 1:50 and 1:250, respectively. A pool of
MRL/lpr /  sera was used as a positive control showing
readily detectable RF in this strain of mice.
Figure 6. Western blot analysis to detect autoanti-
bodies to cellular constituents in sera of NZM2328 and
its congenics. Cell lysate of WEHI 7.1 lymphoma cell
line was used as the substrate with sera at the dilution of
1:50. On the top, sera from mice at 4–5 mo of age
were used with MRL/lpr /  (MRL) pooled sera as the
positive control. Lanes 1–8, NZM.C57Lc1; lanes 9–15,
NZM.C57Lc4; lanes 16–22, NZM2328. On the bottom,
sera at death or at death at the age of 12 mo were used.
Lanes 1–6, NZM.C57Lc1; lanes 7–13, NZM.C57Lc4;
lanes 14–20, NZM2328; lanes 21–24, C57L/J. 
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(histone–DNA complexes) Abs were also detected in these
two congenics. It is important to note that the incidences
of these three autoantibodies were not significantly differ-
ent from those in the nonlupus–prone strain C57L/J. In
addition, the serum IgG concentrations of C57L/J,
NZM2328, and its two congenics were similar.
 
RF and Other Autoantibody Activities in Sera of NZM2328
and Its Congenic Lines.
 
The sera from NZM2328, NZM.-
C57Lc1, and NZM.C57Lc4 females were screened for
RF. As shown in Fig. 5, there were little anti-IgG Ab ac-
tivities in the sera of NZM2328 and its congenic lines. The
lack of RF in C57L/J was also demonstrated. In contrast,
RF activities were readily demonstrated in sera from
MRL/
 
lpr
 
    
 
females. These results were obtained with ei-
ther rabbit IgG or human IgG as the substrate and with sera
either at 1/50 or 1/250 dilutions.
The presence of autoantibodies against cytoplasmic con-
stituents in sera of NZM2328 and its congenics was studied
by Western blot analysis with WEHI 7.1 lymphoma cell
extract as the substrate. Individual serum was used at a 1/50
dilution. By the ages of 4–5 mo, autoantibodies of multiple
specificities were readily detected in NZM2328 females
(Fig. 6, top, lanes 16–22), whereas autoantibodies of lim-
ited reactivities were found in NZM.C57Lc4 (Fig. 6, top,
lanes 9–15). Fewer autoantibodies were detected in the sera
of NZM.C57Lc1 (Fig. 6, top, lanes 1–8). By the time the
mice developed fatal glomerulonephritis, fewer circulating
autoantibodies were detected in NZM2328 (Fig. 6, bot-
tom, lanes 14–20). The sera of NZM.C57Lc4 remained
limited in their autoreactivties (Fig. 6, bottom, lanes 7–13).
By the age of 12 mo, sera of some of the NZM.C57Lc1
and C57L/J showed autoreactivities, whereas others re-
mained nonautoreactive (Fig. 6, bottom, lanes 1–6 and 21–
24). In Fig. 6, a MRL/
 
lpr
 
 
 
/
 
  
 
serum was used as the positive
control to show that both top and bottom panels were de-
veloped to a similar extent in chemiluminescence.
In Fig. 6, some of the sera from both congenic lines and
NZM2328 reacted with proteins of molecular weights be-
tween 30 and 46 kD. Histone H1 with molecular weights
in low 30 kD might be a candidate protein for the target
Ag as revealed by the Western blot analysis. However, in
an ELISA specific for histone H1, no specific anti-H1 Abs
were detected in the sera of NZM2328 and its congenics as
well as in those of C57L/J (unpublished data).
 
Lack of Anti-dsDNA Abs in the Eluates from NZM.C57Lc4
Kidneys Afflicted with Glomerulonephritis.
 
The lack of de-
tectable circulating autoantibodies to dsDNA and other
nuclear Ags in NZM.C57Lc4 despite the presence of im-
mune complex–mediated nephritis is not a definitive proof
that these Abs do not play a pathological role because these
autoantibodies may have been fixed in the kidneys, render-
ing their absence in the blood. To rule out this possibility,
NZM2328, NZM.C57Lc1, NZM.C57Lc4, and C57L/J
females 10–12 mo old were killed. At death, sera were col-
lected and their kidneys were frozen in liquid nitrogen
and stored for elution. Many of the NZM2328 and
NZM.C57Lc4 mice have moderate to severe proteinuria.
The kidneys were homogenized and acid eluates were col-
lected and neutralized. NZM2328 and NZM.C57Lc4 kid-
ney eluates had comparable IgG levels, whereas those of
NZM.C57Lc1 and C57L/J had significantly lower levels of
IgG (unpublished data). Anti-dsDNA Ab activity was ex-
pressed as units/microgram of IgG. As shown in Fig. 7,
anti-dsDNA Abs were detected in the majority of the
NZM2328 sera. There was a concentration of these anti-
dsDNA Abs in the NZM2328 kidneys. The enrichment of
these Abs in the kidneys was 
 
 
 
20-fold. As expected,
few anti-dsDNA Abs were detected in the sera of
NZM.C57Lc1, NZM.C57Lc4, and C57L/J. More impor-
tantly, the kidney eluates of NZM.C57Lc4 rarely had de-
monstrable anti-dsDNA Abs. It is of interest to note that
there was little correlation of anti-dsDNA Ab concentra-
tion in the kidney eluate with serum dsDNA Ab titer in an
individual mouse. In addition, the kidney eluates of
NZM.C57Lc1, NZM.C57Lc4, and C57L/J did not show
antinuclear reactivity on HeLa cells. There was staining for
ANA with NZM2328 kidney eluates when they were used
without dilution. As with sera, the sera and their paired
kidney eluates were also studied regarding RF. The kidney
eluates of NZM2328, NZM.C57Lc1, NZM.C57Lc4, and
C57L/J did not have detectable RF. These results support
our hypothesis that ANA and RF play no significant role
in the kidney disease in NZM2328 and its congenic
NZM.C57Lc4.
Figure 7. Anti-dsDNA Ab in sera and kidney eluates from NZM2328,
NZM.C57Lc1, NZM.C57Lc4, and C57L/J females at 11–12 mo. Abs to
dsDNA were present in sera of NZM2328 and they were enriched in
their kidney eluates. These Abs were rarely detected in the sera and the
kidney eluates of the other three strains. P-values indicate significant
differences of the respective strain as compared with NZM2328. 
Waters et al.
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Eluates from NZM.C57Lc4 Diseased Kidneys Identified
Several Target Ags.
 
Kidney and liver from 8-wk-old
NZM2328 were perfused with cold PBS. Extracts of them
were used as substrates for Western blot analysis. Kidney
eluates from NZM2328 and NZM.C57Lc4 were used at
either 30 or 10 
 
 
 
g/ml for assaying Ab activity to these ex-
tracts. The results are summarized in Fig. 8. Both eluates
from NZM2328 and NZM.C57Lc4 kidneys stained several
bands in the region between molecular weights of 25 and
40 kD in the kidney extract. The eluate from NZM2328
also had activities against proteins of higher molecular
weights. Although the bands were not distinct, proteins of
a lower molecular weight of 
 
 
 
21 kD were also reactive
with the NZM2328 eluate. It appears that the reactive Ags
are also present in the liver extract. Similar results were ob-
tained in another experiment.
 
Discussion
 
Breaking Tolerance to dsDNA and Related Nuclear Ags Is
Not Required for the Pathogenesis of Lupus Glomerulonephritis.
 
The most significant finding in this investigation is that de-
spite the lack of circulating ANA, anti-dsDNA and antinu-
cleosome Ab, chronic glomerulonephritis, severe pro-
teinuria, and early mortality are found in a high proportion
of NZM.C57Lc4 females. The eluates of kidneys from
both congenics at 12 mo of age did not contain significant
amounts of anti-dsDNA Ab, whereas the eluate from the
NZM2328 kidneys had a significant amount of such Ab.
There were no significant ANA titers in the sera and kid-
ney eluates of these congenic lines. These data would sup-
port the conclusion that tolerance to dsDNA and related
nuclear Ags remains intact in aged NZM.C57Lc4 despite
the development of fatal glomerulonephritis. Thus, it is
reasonable to conclude that lupus glomerulonephritis can
occur in the absence of these autoantibodies and that
breaking tolerance to nuclear Ags and dsDNA need not be
the initial or necessary step in the pathogenesis of lupus ne-
phritis as postulated by others (11–16).
 
Target Ags for Nephritogenic Ab in NZM.C57Lc4.
 
Lu-
pus nephritis has been considered to be a prototype of im-
mune complex–mediated disease. The Ab–Ag systems in-
volved have been an important area of investigation for
both basic and clinical investigators. Shortly after the dem-
onstration by Holman and Kunkel (25) that DNA is a target
Ag in ANA, the importance of the dsDNA and anti-
dsDNA Ab system in the pathogenesis of SLE was illus-
trated in two seminal papers from the laboratory of the late
Henry Kunkel (3, 4). The involvement of RF in lupus ne-
phritis was shortly demonstrated thereafter (26). Recently,
Mannik et al. (27) have reported that anti-dsDNA, anti-
snRNP, anti-Ro/La, anti-IgG, and antihistone autoantibod-
ies and autoantibodies of other specificities account for 
 
 
 
25%
of IgG eluted from kidneys of SLE patients with severe glo-
merulonephritis. These studies suggest that more attention
to Ag–Ab systems other than that of dsDNA and anti-
dsDNA Ab might be warranted for our further understand-
ing of SLE pathogenesis. In this regard, the NZM.C57Lc4
line, which contains high levels of glomerular IgG but not
glomerular anti-dsDNA Ab and RF, will serve as an excel-
lent model for further investigation of this important issue.
The role of Ab and B cells in the pathogenesis of lupus
nephritis has been recently reviewed by Shlomchik and Ma-
daio (28). Crossreactive and direct reactive Ab to renal Ag
has been postulated to be an important mechanism for IgG
deposition. A 108-kD renal mesangial Ag was identified to
be the renal target for a monoclonal Ab to dsDNA (29).
The 100-kD 
 
 
 
-actinin has also been recently identified as
the target Ag for other anti-dsDNA Abs (30, 31). In our in-
vestigation, several Ags in the range of molecular weight
25–40 kD were reactive with the NZM.C57Lc4 kidney
eluate. The identity of these Ags is currently under investi-
gation. The kidney eluate from the parental line NZM2328
had Ab activity to proteins of higher molecular weight. One
of these might be 
 
 
 
-actinin. In addition to Ab-mediated in-
jury, evidence for a role of T cells in the pathogenesis of lu-
pus nephritis is accumulating. Bloom et al. (32) have shown
that intrathymically injected kidney cells delay the onset of
lupus nephritis in MRL 
 
lpr/lpr
 
 mice. More directly, Chan et
al. (33) have reported a unique form of nephritis in the
MRL 
 
lpr/lpr
 
 mice, which have B cells without circulating
Ig. These mice have a shortened lifespan, intermediate be-
tween the wild-type and that without B cells. These studies
provide evidence that T cells play a crucial role by direct
Figure 8. Abs eluted from nephritic kidneys of NZM2328 and
NZM.C57Lc4 mice are reactive with proteins within the kidney and
liver extracts. Proteins in the kidney (left) and liver (right) extracts were
separated on a 12% SDS-PAGE, transferred to nitrocellulose paper, and
used for analyzing the reactivity of Abs eluted from the nephritic kidneys
of NZM2328 (lanes 2 and 3) and NZM.C57Lc4 (lanes 4 and 5) mice.
Each lane is equivalent to 60  g total protein. Abs were used at a concen-
tration of 30 (lanes 2 and 4) and 10  g/ml (lanes 3 and 5). Lane 1 in both
panels represents reactivity of the goat anti–mouse IgG–horseradish
peroxidase conjugate with the extracts. Numbers on the left represent
molecular weights in kilodaltons. 
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participation in end organ damage. In our preliminary stud-
ies, lymphocytes in the draining lymph nodes of the kidneys
were found to be selectively activated by the age of 8 wk in
NZM2328. This suggests that an immune response involv-
ing both T and B cells to kidney Ags may play an important
role in the pathogenesis of lupus nephritis. This result also
suggests that the kidney should be considered an active par-
ticipant in this process.
 
SLE Susceptibility Genes.
 
In NZM2328, SLE suscepti-
bility genes 
 
Agnz1
 
 and 
 
Cgnz1
 
 controlling acute and
chronic glomerulonephritis, respectively, were identified at
the distal distinct regions of chromosome 1 (19). The con-
genic line NZM.C57Lc1 has markedly reduced incidence
of severe proteinuria and chronic glomerulonephritis al-
though the incidence of acute glomerulonephritis is re-
duced to a lesser degree. These phenotypes are expected,
confirming the quantitative genetic trait analytical data and
the importance of a single gene 
 
Cgnz1
 
 in controlling
chronic glomerulonephritis. The marked reduction of cir-
culating ANA, anti-dsDNA, and antinucleosome Ab in
NZM.C57Lc1 is unexpected. This finding implicates a sec-
ond locus, 
 
Adnz2
 
 (Anti-dsDNA antibody in NZM2328
locus 2) within this region, to be linked to ANA, anti-
dsDNA, and antinucleosome production. The location of
 
Adnz2
 
 remains to be determined. Because NZM.C57Lc1
expresses 
 
Adnz1
 
, which is located on chromosome 4 (19),
 
Adnz1
 
 and 
 
Adnz2
 
 must interact with each other to express
the phenotype of anti-dsDNA Ab production, providing
evidence for the complexity of genetic control of this
seemingly simple phenotype.
The congenic line NZM.C57Lc1, in which the interval
of interest was replaced by that of C57L/J, has provided us
the capability to generate intrachromosomal recombinants to
determine whether distinct subregions within this interval
control these three phenotypes. Several such intrachromo-
somal recombinants have been generated and their pheno-
types are being determined. These recombinants will also
provide us data to determine whether 
 
Adnz2
 
 represents sev-
eral clusters of genes, each of which can independently con-
trol ANA, anti-dsDNA, and antinucleosome Ab production.
 
Proposed Model for the Pathogenesis of Lupus Nephritis.
 
The findings reported here have significant implications on
our thinking of the pathogenesis of SLE. An alternative and
a less anti-dsDNA– and antinucleosome Ab–centric model
for the pathogenesis of SLE is put forth and depicted in Fig.
9. In this model, autoantibody production and autoreactive
T cell generation (Fig. 9, pathway I) and activation of genes
leading to end organ damage (Fig. 9, pathway II) are inde-
pendent events. Activation of the autoimmune response is
either as a result of genetic predisposition or environmental
factors such as chemical exposure and infections. Genes
controlling end organ susceptibility exert their influence on
the targeted end organs by causing differential expression of
genes and/or increased apoptosis in target organs, which
may lead to overexpression of organ-specific Ag. The initi-
ation of these two pathways might be independent of each
other. This is supported by both clinical and experimental
data. Clinically, many patients with significant titers of
ANA do not have symptoms and signs of SLE. Specifically,
they do not have end organ damage. In experimental mod-
els such as NZM2328, male mice have significant eleva-
tions of ANA and anti-dsDNA Ab without chronic glo-
merulonephritis. The recent work by Jacob et al. (34),
shows that Stat4-deficient NZM2328 developed acceler-
ated nephritis and increased mortality with lower titers of
anti-DNA Ab. In contrast, Stat6-deficient NZM2328 mice
Figure 9. Interactive model for the pathogenesis of
SLE. Pathway I, autoantibody production and activation
of effector T cells and pathway II, activation of suscep-
tibility genes and end organ damage, can be initiated
independently while they interact at different levels as
indicated by pathways III and IV. The interactions
between these pathways lead to end organ damage. 
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had a significant reduction of nephritis despite the presence
of high levels of anti-DNA Ab.
The recent work by Singh et al. (35) shows that cytokines
have differential effects on kidney disease in NZM2410. It is
plausible that enhanced cytokines and chemokine expres-
sion as a result of activation of the innate and adaptive im-
mune systems can increase target organ susceptibility. De-
spite the independence of the initiation of these two
pathways, they do interact with each other (Fig. 9, pathway
III). These interactions may influence differential gene ex-
pression and induce organ-specific Ab production as well as
tissue-specific effector T cell generation (Fig. 9, pathway
IV). In this regard, the importance of cell death in autoim-
mune thyroid disease has been well documented (36) and
the administration of a caspase inhibitor has been shown to
inhibit the development of lupus nephritis without affecting
autoantibody production or skin inflammation (37).
The proposed model accommodates most of the data ac-
cumulated both by clinical observations and animal investi-
gations. This model also implicitly states that dampening
the ongoing inflammatory response present in SLE patients
influences both the activation states of immune cells and
the susceptibility of end organ damage and should be a ma-
jor target in the therapeutic approach to SLE.
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